What happens when a patent expires on a branded drug?

A generic drug is a pharmaceutical that contains the same chemical substance as a drug that was originally branded and protected by patents, but once they expire, duplicates are often allowed for sale as so-called generics.

Some characteristics such as the manufacturing process, formulation, color, taste, and packaging may slightly differ, but given that the active pharmaceutical ingredient (API) is the same, the medical profile of generics is believed to be equivalent in performance to the original and therefore its route to market it much quicker.

In order to market them, manufacturers must still conduct studies to determine whether their version is bioequivalent to the original drug; specifically, that its active ingredient releases into the bloodstream at virtually the same speed and amount, but as the original was already proven safe, the testing is much quicker and requires a much smaller clinical study.

QUINTA-ANALYTICA’s bioanalytical department has vast experience in drug testing, and has developed and validated over 300 bioanalytical methods for APIs under GLP, GMP, and ICH/FDA and EMEA directives.

Get in touch with us today to discuss your testing needs.

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.